Reports

Drug name	NICE TAs	Comments
Bendroflumethiazide tablets		2.5mg dose (higher doses not indicated in hypertension). Most patients do not develop hypokalaemia. Suggest check potassium level one month after initiation and annually thereafter (MeReC 10/94)
Betaine anhydrous powder (180g)		NHSE commissioned.
Betamethasone 0.1%, neomycin 0.5% eye drops		Short term use only
Betamethasone valerate 0.025% cream	TA85 - Frequency of application of topical corticosteroids for atopic eczema	Betnovate RD. Moderate potency.
Betamethasone valerate 0.025% ointment	TA85 - Frequency of application of topical corticosteroids for atopic eczema	Betnovate RD. Moderate potency.
Betamethasone valerate 0.1% cream	TA85 - Frequency of application of topical corticosteroids for atopic eczema	Betnovate®. Potent potency.
Betamethasone valerate 0.1% ointment	TA85 - Frequency of application of topical corticosteroids for atopic eczema	Betnovate®. Potent potency.
Betamethasone valerate 0.1% scalp application	TA85 - Frequency of application of topical corticosteroids for atopic eczema	Betnovate®. Potent potency.
Betaxolol eye drops		Specialist ophthalmologist recommendation 0.25% ophthalmic suspension 0.5% eye drops 0.5% unit dose eye drops
Bevacizumab infusion (Avastin®)	TA178 - Bevacizumab (first-line), sorafenib (first and second line), sunitinib (second-line) and temsirolimus (first-line) for the treatment of advanced and/or metastatic renal cell carcinoma TA212 - Bevacizumab in combination with oxaliplatin and either fluorouracil plus folinic acid or capecitabine for the treatment of metastatic colorectal cancer TA242 - Cetuximab, bevacizumab and panitumumab for the treatment of metastatic colorectal cancer after first-line chemotherapy: Cetuximab (monotherapy or combination chemotherapy), bevacizumab (in combination with non-oxaliplatin chemotherapy) and panitumumab (monotherapy) for the treatment of metastatic colorectal cancer after first-line chemotherapy TA214 - Bevacizumab in combination with a taxane for the first-line treatment of metastatic breast cancer TA263 - Bevacizumab in combination with capecitabine for the first-line treatment of metastatic breast cancer TA284 - Bevacizumab in combination with paclitaxel and carboplatin for first-line treatment of advanced ovarian cancer TA285 - Bevacizumab in combination with gemcitabine and carboplatin for treating the first recurrence of platinum-sensitive advanced ovarian cancer	Negative NICE TA & hospital use only.

First page
Previous page
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
Next page
Last page

University Hospitals Birmingham NHS Foundation Trust

Medicines Formulary

Reports